Advertisement

Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas

  • Y.S. Kushchayeva
  • S.H. Tella
  • S.V. Kushchayev
  • D. Van Nostrand
  • K. KulkarniEmail author
Original Article
  • 28 Downloads

Abstract

Summary

Tc99m-sestamibi dual-time imaging is a standard tool for localization of adenomas/hyperplasia in hyperparathyroidism. We investigated the degree and causes of localization failure among different types of hyperparathyroidism. Pre-operative parathyroid hormone levels and size of the gland were major determinants of Tc99m-sestamibi positivity; 123I scan may be helpful in localization failures.

Introduction

Tc99m-sestamibi dual-time imaging is a standard tool for localization of adenomas/hyperplasia in hyperparathyroidism. However, parathyroid adenomas/hyperplasia has been reported to washout as fast as normal thyroid tissue (“rapid washout”) which may lead to diagnostic failure. We aimed to evaluate the determinants of rapid washout and to determine the role of subtraction imaging for detection of parathyroid adenomas/hyperplasia with rapid washout.

Methods

Retrospective analysis of patients with hyperparathyroidism who have undergone Tc99m-sestamibi dual-time imaging and parathyroid surgery. Rapid washout was correlated to the type of hyperparathyroidism in surgically confirmed cases. Biochemical and pathological data were reviewed.

Results

A total of 135 hyperparathyroidism patients met the inclusion criteria. Ninety-six (72%), 29 (21%), and 10 (7%) had primary, secondary, and tertiary hyperparathyroidisms, respectively. Rapid washout was identified in 28/87 glands (32%), 14/53 glands (26%), and 1/16 glands (6%) with primary, secondary, and tertiary hyperparathyroidisms, respectively. Glands that were positive on late-phase Tc99m-sestamibi scans were significantly large being 1.7 (IQR 1.4–2.3) vs. 1.45 (IQR 1–2) cm (p = 0.003). High parathyroid hormone levels (PTH) were associated with early-phase Tc99m-sestamibi positivity in both primary (p = 0.01) and secondary hyperparathyroidism (p = 0.03) but not with last phase (p = 0.11, p = 0.37, respectively). Correlative imaging with subtraction scintigraphy was positive in 14/16 (87.5%) parathyroid adenomas.

Conclusion

Pre-operative PTH levels and size of the gland were major determinants of Tc99m-sestamibi positivity on early-phase Tc99m-sestamibi scans, whereas size is an independent predictor of late-phase Tc99m-sestamibi positivity. Subtraction scintigraphy might be a useful tool in suspected cases of rapid washout adenomas/hyperplasia.

Keywords

Hyperparathyroidism Parathyroid adenomas Rapid washout PTH 

Notes

Acknowledgements

The work was presented as a poster at Endocrine Society’s annual meeting proceedings 2017, Orlando, FL.

Compliance with ethical standards

The corresponding author’s (K.K) institutional review board approved the study.

Conflict of interest

None.

References

  1. 1.
    Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot J-N (2015) A pilot comparison of (18)F-fluorocholine PET/CT, ultrasonography and (123)I/(99m)Tc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine 94(41):e1701.  https://doi.org/10.1097/MD.0000000000001701 CrossRefGoogle Scholar
  2. 2.
    Pitt SC, Sippel RS, Chen H (2009) Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am 89(5):1227–1239.  https://doi.org/10.1016/j.suc.2009.06.011 CrossRefGoogle Scholar
  3. 3.
    Kluijfhout WP, Vorselaars WM, Vriens MR, Borel Rinkes IH, Valk GD, de Keizer B (2015) Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol 84(9):1745–1751.  https://doi.org/10.1016/j.ejrad.2015.05.024 CrossRefGoogle Scholar
  4. 4.
    Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE (1989) 99Tcm sestamibi—a new agent for parathyroid imaging. Nucl Med Commun 10(11):791–794CrossRefGoogle Scholar
  5. 5.
    Bergenfelz A, Tennvall J, Valdermarsson S, Lindblom P, Tibblin S (1997) Sestamibi versus thallium subtraction scintigraphy in parathyroid localization: a prospective comparative study in patients with predominantly mild primary hyperparathyroidism. Surgery 121(6):601–605CrossRefGoogle Scholar
  6. 6.
    Caveny SA, Klingensmith WC 3rd, Martin WE, Sage-El A, McIntyre RC Jr, Raeburn C, Wolfe P (2012) Parathyroid imaging: the importance of dual-radiopharmaceutical simultaneous acquisition with 99mTc-sestamibi and 123I. J Nucl Med Technol 40(2):104–110.  https://doi.org/10.2967/jnmt.111.098400 CrossRefGoogle Scholar
  7. 7.
    Lopez AJ, Scheer JK, Leibl KE, Smith ZA, Dlouhy BJ, Dahdaleh NS (2015) Anatomy and biomechanics of the craniovertebral junction. Neurosurg Focus 38(4):E2.  https://doi.org/10.3171/2015.1.FOCUS14807 CrossRefGoogle Scholar
  8. 8.
    Neumann DR, Obuchowski NA, Difilippo FP (2008) Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med 49(12):2012–2017.  https://doi.org/10.2967/jnumed.108.054858 CrossRefGoogle Scholar
  9. 9.
    Chen CC, Holder LE, Scovill WA, Tehan AM, Gann DS (1997) Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT. J Nucl Med 38(6):834–839Google Scholar
  10. 10.
    Cermik TF, Puyan FO, Sezer A, Firat MF, Berkarda S (2005) Relation between Tc-99m sestamibi uptake and biological factors in hyperparathyroidism. Ann Nucl Med 19(5):387–392CrossRefGoogle Scholar
  11. 11.
    Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I, Abdel-Dayem HM (1997) Role of thallium-201 chloride and Tc-99m methoxy-isobutyl-isonitrite (sestaMIBI) in evaluation of breast masses: correlation with the immunohistochemical characteristic parameters (Ki-67, PCNA, Bcl, and angiogenesis) in malignant lesions. Anticancer Res 17(3B):1639–1644Google Scholar
  12. 12.
    Neumann DR, Esselstyn CB, Maclntyre WJ, Go RT, Obuchowski NA, Chen EQ, Licata AA (1996) Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 37(11):1809–1815Google Scholar
  13. 13.
    Lorberboym M, Minski I, Macadziob S, Nikolov G, Schachter P (2003) Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. J Nucl Med 44(6):904–908Google Scholar
  14. 14.
    Arveschoug AK, Bertelsen H, Vammen B, Brochner-Mortensen J (2007) Preoperative dual-phase parathyroid imaging with tc-99m-sestamibi: accuracy and reproducibility of the pinhole collimator with and without oblique images. Clin Nucl Med 32(1):9–12.  https://doi.org/10.1097/01.rlu.0000249401.48030.9c CrossRefGoogle Scholar
  15. 15.
    Krause MW, Hedinger CE (1985) Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 16(8):772–784CrossRefGoogle Scholar
  16. 16.
    Ritter CS, Haughey BH, Miller B, Brown AJ (2012) Differential gene expression by oxyphil and chief cells of human parathyroid glands. J Clin Endocrinol Metab 97(8):E1499–E1505.  https://doi.org/10.1210/jc.2011-3366 CrossRefGoogle Scholar
  17. 17.
    Christie AC (1967) The parathyroid oxyphil cells. J Clin Pathol 20(4):591–602CrossRefGoogle Scholar
  18. 18.
    Vijayakumar V, Anderson ME (2005) Detection of ectopic parathyroid adenoma by early Tc-99m sestamibi imaging. Ann Nucl Med 19(2):157–159CrossRefGoogle Scholar
  19. 19.
    Sandrock D, Merino MJ, Norton JA, Neumann RD (1993) Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid subtraction scintigraphy. J Nucl Med 34(1):24–29Google Scholar
  20. 20.
    Benard F, Lefebvre B, Beuvon F, Langlois MF, Bisson G (1995) Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. J Nucl Med 36(2):241–243Google Scholar
  21. 21.
    Schachter PP, Issa N, Shimonov M, Czerniak A, Lorberboym M (2004) Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy. Arch Surg 139(4):433–437.  https://doi.org/10.1001/archsurg.139.4.433 CrossRefGoogle Scholar
  22. 22.
    Pons F, Torregrosa JV, Fuster D (2003) Biological factors influencing parathyroid localization. Nucl Med Commun 24(2):121–124.  https://doi.org/10.1097/01.mnm.0000057324.59072.67 CrossRefGoogle Scholar
  23. 23.
    Ambrosoni P, Heuguerot C, Olaizola I, Acuna G, Fajardo L, Petraglia A, Caorsi H, Lopez J, Kurdian M, Jorgetti V, Aznarez A (1998) Can we use 99mTc-MIBI in functional studies of the parathyroid gland? Nephrol Dial Transplant 13(Suppl 3):33–36CrossRefGoogle Scholar
  24. 24.
    Torregrosa JV, Palomar MR, Pons F, Sabater L, Gilabert R, Llovera J, Fernandez-Cruz L (1998) Has double-phase MIBI scintigraphy usefulness in the diagnosis of hyperparathyroidism? Nephrol DialTransplant 13(Suppl 3):37–40CrossRefGoogle Scholar
  25. 25.
    Hung GU, Wang SJ, Lin WY (2003) Tc-99m MIBI parathyroid scintigraphy and intact parathyroid hormone levels in hyperparathyroidism. Clin Nucl Med 28(3):180–185.  https://doi.org/10.1097/01.RLU.0000053529.71776.37 Google Scholar
  26. 26.
    Dugonjic S, Sisic M, Radulovic M, Ajdinovic B (2017) Positive 99mTc-MIBI and the subtraction parathyroid scan are related to intact parathyroid hormone but not to total plasma calcium in primary hyperparathyroidism. Hell J Nucl Med 20(1):46–50.  https://doi.org/10.1967/s002449910506 Google Scholar
  27. 27.
    Staudenherz A, Abela C, Niederle B, Steiner E, Helbich T, Puig S, Kaserer K, Becherer A, Leitha T, Kletter K (1997) Comparison and histopathological correlation of three parathyroid imaging methods in a population with a high prevalence of concomitant thyroid diseases. Eur J Nucl Med 24(2):143–149CrossRefGoogle Scholar
  28. 28.
    Melloul M, Paz A, Koren R, Cytron S, Feinmesser R, Gal R (2001) 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur J Nucl Med 28(2):209–213CrossRefGoogle Scholar
  29. 29.
    Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ, Maheux P (1998) Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med 39(8):1441–1444Google Scholar
  30. 30.
    Lane MJ, Desser TS, Weigel RJ, Jeffrey RB Jr (1998) Use of color and power Doppler sonography to identify feeding arteries associated with parathyroid adenomas. AJR Am J Roentgenol 171(3):819–823.  https://doi.org/10.2214/ajr.171.3.9725323 CrossRefGoogle Scholar
  31. 31.
    Hassler S, Ben-Sellem D, Hubele F, Constantinesco A, Goetz C (2014) Dual-isotope 99mTc-MIBI/123I parathyroid scintigraphy in primary hyperparathyroidism: comparison of subtraction SPECT/CT and pinhole planar scan. Clin Nucl Med 39(1):32–36.  https://doi.org/10.1097/RLU.0000000000000272 CrossRefGoogle Scholar
  32. 32.
    Hindie E, Melliere D, Jeanguillaume C, Perlemuter L, Chehade F, Galle P (1998) Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. J Nucl Med 39(6):1100–1105Google Scholar
  33. 33.
    Neumann DR, Esselstyn CB Jr, Madera A, Wong CO, Lieber M (1998) Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography. J Clin Endocrinol Metab 83(11):3867–3871.  https://doi.org/10.1210/jcem.83.11.5241 CrossRefGoogle Scholar
  34. 34.
    Jorna FH, Jager PL, Que TH, Lemstra C, Plukker JT (2007) Value of 123I-subtraction and single-photon emission computed tomography in addition to planar 99mTc-MIBI scintigraphy before parathyroid surgery. Surg Today 37(12):1033–1041.  https://doi.org/10.1007/s00595-007-3550-4 CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Diabetes, Endocrinology, and Obesity Branch, NIDDKNIHBethesdaUSA
  2. 2.University of South Carolina School of MedicineColumbiaUSA
  3. 3.Department of RadiologyJohns Hopkins HospitalBaltimoreUSA
  4. 4.Division of Nuclear MedicineMedStar Washington Hospital CenterWashingtonUSA

Personalised recommendations